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Abstract
Heparin-induced thrombocytopenia (HIT) is the most life-threatening adverse 
effect of heparin therapy and is provoked by the development of drug-dependent 
antibodies. It occurs more frequently in patients with cardiac or orthopedic surgery 
or severe circulatory diseases, and the risk depends on the patient pathological 
status. As heparin is an anticoagulant used for treating thrombotic events or their 
risk, this iatrogenic complication has a paradoxal effect as it can induce throm-
boembolic diseases, frequently associated to severe morbidity or fatal outcomes. 
Diagnosis involves clinical evaluation of disease probability and laboratory tools for 
testing the presence of heparin-dependent antibodies with immunoassays or their 
capability to activate platelets with functional assays. Antibodies developed when 
stoichiometric complexes of platelet factor 4 (PF4) with heparin are formed during 
therapy. In few cases non-platelet factor 4 antigens can be involved. Antibodies can 
remain asymptomatic, but pathogenicity occurs in the presence of high concentra-
tions of IgG isotype antibodies, with high avidity: they target and activate platelets 
or endothelial cells exposing heparin-PF4 (HPF4) complexes and produce throm-
bocytopenia and sometimes thrombosis. Risk factors which favor the development 
of antibodies and their pathological effect are discussed. The present understanding 
of mechanisms underlying disease development and diagnostic strategies of this 
heparin adverse effect is presented.
Keywords: platelet factor 4, heparin, antibodies, pathogenicity, thrombosis, 
thrombocytopenia, diagnosis
1. Introduction
The major adverse effect of heparin therapy concerns probably the develop-
ment of thrombocytopenia and thromboembolic complications, which are directly 
caused by the drug itself [1–6]. This heparin paradox is associated with a character-
istic platelet fall and thrombosis in some heparin-treated patients, especially when 
unfractionated heparin (UFH) is used, but it can also occur with low molecular 
weight heparin (LMWH) therapy. The patient’s clinical context can favor the 
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development of this iatrogenic complication, called heparin-induced thrombocyto-
penia (HIT) without or with associated thrombosis (HITT). When this complica-
tion occurs, it requires an immediate management with the withdrawal of heparin 
and use of an alternative anticoagulant [7–11]. If incorrectly managed, it can rapidly 
cause severe burden and become life-threatening. This complication is reported to 
occur in about 1–5% of patients treated with UFH and 0.2–0.5% of those treated 
with LMWH, but the incidence highly depends on the clinical context [1, 3, 5, 6]. 
Cardiology or orthopedic surgery, trauma, circulatory diseases, and the presence 
of tumors are increased risk factors for that disease. A recent meta-analysis in the 
USA reported a different HIT/HITT incidence and clinical association than that 
usually accepted but shows that it remains a critical clinical issue in hospitals [5]. 
The first alert signal for HIT is a platelet count drop by more than 30–50% between 
two successive measures, occurring between 5 and 15 days following the onset of 
heparin therapy, in the absence of any other thrombocytopenia cause (Table 1). 
However, platelet fall can develop earlier if patients have been exposed to heparin 
during the 3 months preceding the treatment. The mechanisms producing HIT 
involve the generation of a heparin-dependent antibody, usually of the IgG isotype 
(but IgA and IgM isotypes can also be present). This antibody has been demon-
strated to be targeted to complexes of heparin and platelet factor 4 (PF4) in most 
of the cases [12, 13], but non-PF4 antigens can be present in some atypical patients 
[14–17]. Frequently, heparin-dependent antibodies, including IgG isotypes, are 
asymptomatic [18, 19]. They are symptomatic and harmful only in a few subsets of 
affected patients. What renders the antibodies pathogenic in those patients is not 
totally understood, but some evidence becomes available. IgG isotypes present at 
high concentration, and with high avidity, provoke frequently the development of 
disease [19, 20]. Clinical diagnosis and laboratory diagnosis are of high importance 
to rapidly identify the patients with an active disease and treat them [6, 8, 21–24]. It 
includes a multiple strategy approach:
1. early detection of patients with thrombocytopenia
2. evaluation of their HIT clinical score
3. testing for the presence of heparin-dependent antibodies with immunoassays
4. checking the capability of these antibodies to activate platelets in a heparin-
dependent mode [25].
It is of essence to duly characterize patients with HIT: if this complication is 
excluded, it is not necessary to deprive them from heparin, as it is the most effective 
anticoagulant in many acute conditions. Conversely, if HIT/HITT is confirmed, it is 





• Heparin therapy duration (≥5 days)
• Re-exposure to heparin <100 days
Table 1. 
Risk factors for HIT development during heparin therapy.
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mandatory to not reintroduce any heparin treatment and to switch to an alternative 
anticoagulation. In this book chapter, we will present and discuss the following: (a) 
the present understandings of conditions which can favor development of heparin-
dependent antibodies in heparin-treated patients; (b) why antibodies generate HIT 
or HITT only in a few subset of patients; (c) the mechanisms of action of these anti-
bodies, as they are presently understood; (d) the available laboratory tools and their 
indications; (e) the diagnostic strategy for rapidly characterizing patients at risk; 
(f) the occurrence of atypical presentations of HIT in patients with pre-existing 
antibodies to PF4 or to interleukin 8 (IL8) or with antibodies to protamine sulfate 
(PrS); and (g) cross-reactivity of the various polysaccharide anticoagulants in 
immunoassays and functional methods. This chapter mainly focuses on antibodies 
generated to heparin-PF4 (HPF4) complexes, which concern most of the patients 
with HIT/HITT, but other non-PF4 antigens can be involved in few cases and will 
be rapidly discussed.
2. Development of heparin-induced thrombocytopenia
Heparin-dependent antibodies develop in many patients treated with UFH or 
LMWH. Their incidence is higher in patients undergoing extracorporeal circula-
tion (ECC) for cardiopulmonary bypass (CPB) or extracorporeal membrane 
oxygenation (ECMO) [5, 26, 27]. Antibodies’ development is not rare during 
heparin therapy, but they are often of the IgM isotype with a rapid reversal with-
out any clinical incidence [18, 19]. They can also be of the IgA or IgG isotypes, 
and the three isotypes are associated in many patients and are frequently asymp-
tomatic. IgGs have been demonstrated to be those which can become pathogenic, 
especially when present at high concentration, with high affinity for their target 
heparin-dependent antigen [19, 25]. A subset of the IgG isotype heparin-depen-
dent antibodies can then activate platelets [20], which induce thrombocytopenia, 
platelet aggregation, and sometimes thrombosis. HIT was first characterized for 
the white thrombus formed in arteries (platelets and white blood cells), when 
patients with this complication were first identified, but there is evidence now 
that arterial (about 30% of cases) or venous (about 70% of cases) thrombosis can 
occur [28]. Skin necrosis at the injection site or elsewhere, or thrombosis, fre-
quently at limb extremities, is often observed, but thrombosis can occur at many 
different sites.
In addition to platelet activation, heparin-dependent antibodies can induce 
activation of endothelial cells (ECs) and of monocytes, and they can release tissue 
factor (TF) from these cells, which contribute to thrombosis [29–31]. Platelet-
leukocyte aggregates are also formed and contribute to thrombogenicity. When this 
multiple blood activation process is initiated, it is enhanced at pathological sites 
where platelet and white blood cells can be chemo-attracted and accumulate with 
a high density. If blood activation and prothrombotic process are strong enough to 
overwhelm the antithrombotic body’s defenses, thrombus formation occurs. The 
first clinical warning for HIT is the occurrence of thrombocytopenia, with a char-
acteristic time kinetics from the onset of therapy, when other causes of decreased 
platelet counts are excluded [6, 25, 28]. Platelet fall typically occurs between 5 
and 15 days following the initiation of treatment, as shown in Figure 1, except if 
patients already received heparin within the 100 preceding days or in the rare cases 
with pre-existing anti-PF4 antibodies. Thrombocytopenia can then develop earlier 
and possibly just at the onset of heparin therapy. In HIT/HITT thrombocytopenia is 
usually moderate, between 20 and 100 giga platelets per liter (G/L), and it is rarely 
very severe (<10 G/L). When it develops, the clinical probability for HIT/HITT  
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must be evaluated. It is an important criterion for estimating the risk to develop 
this complication in heparin-treated patients, and various pretest methods for 
estimating disease risk are available. The most frequently used is the 4Ts score [28], 
which considers four major criteria: the presence of thrombocytopenia, the tim-
ing of platelet count fall, the occurrence of new thrombosis or sequelae, and the 
investigation of other causes of thrombocytopenia. For each criterion, a score from 
0 to 2 is given, as shown in Table 2. It allows to classify patients from 0 to 8 (risk is 
low for 0–3, intermediate for 4–5, and high for ≥6, indicating an elevated disease 
probability). In cardiology patients with ECC, thrombocytopenia is frequently 
observed, and HIT can be identified when a biphasic platelet count kinetics is 
present: in the absence of HIT, thrombocytopenia is progressively corrected, but, if 
present, platelet count starts to increase and falls again when symptomatic antibod-
ies develop [27].
Figure 1. 
Typical platelet count kinetics in heparin-treated patients who develop heparin-dependent antibodies 
responsible for heparin-induced thrombocytopenia.
Table 2. 
The pretest probability for HIT based on the 4Ts score.
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Other HIT clinical evaluation approaches have been proposed (such as the 
expert score), but the 4Ts score remains the most widely used. When HIT is sus-
pected, heparin treatment must be stopped and replaced by another anticoagulant. 
The possible drugs which can be used include argatroban, direct oral anticoagulants 
(DOACs), danaparoid sodium, fondaparinux, and bivalirudin [7, 9–11, 32, 33].  
Nevertheless, if HIT is excluded, heparin can be reintroduced, as it can be of full 
benefit for the patient, especially in cardiac surgery and circulatory diseases. 
Establishing rapidly a safe and reliable diagnosis of HIT is then of essence for the 
right management of patients [6, 25, 28].
3. Heparin-dependent antibodies in clinical settings
HIT/HITT occurs in some of the patients who develop heparin-dependent 
antibodies, a major risk factor for the disease occurrence. In most of the cases, 
they are targeted to stoichiometric complexes of heparin and PF4 (HPF4) and 
are of the IgG isotype but are the only ones present in few patients with atypical 
HIT/HITT antibodies to IL8 or to PrS [12, 14, 15, 17]. In rare cases, the antibody 
specificity remains non-identified, although patients present the suggestive clinical 
complication of heparin therapy. What causes the heparin-dependent antibodies’ 
generation is not yet fully understood, but drug immunogenicity tends to develop 
when heparin forms complexes with its high-affinity binding blood protein, PF4, 
a chemokine from the CXC family [34–36], and eventually IL8 [37, 38]. In healthy 
individuals, PF4 is normally present at very low concentrations in blood circulation 
(<10 ng/ml). It is released from platelets’ α-granules upon activation or aggrega-
tion, as a complex of eight PF4 tetramers with a platelet proteoglycan dimer, with 
a molecular weight (MW) of about 350 kDa. This complex is rapidly cleared from 
circulation as PF4 is captured by endothelial cells’ glycosaminoglycans (GAGs) and 
Figure 2. 
At the onset of heparin therapy, TFPI and PF4 “storage pool” are displaced from endothelial cells and released 
into blood circulation. Heparin complexes with PF4, and this can stimulate the immune system (especially if 
heparin and PF4 stoichiometric concentrations are met), and antibodies to these complexes are generated.
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remains in this endothelial storage pool. In patients with inflammation or blood 
activation, PF4 concentrations can be much higher, either in blood circulation 
or on the endothelial storage pool. In addition, at pathological sites, platelets and 
white blood cells can be chemo-attracted and stimulated. Much higher PF4 concen-
trations can be present at these sites. At the onset of heparin therapy, PF4, which 
has a higher affinity for this drug than for GAGs or physiological proteoglycans, 
forms complexes with it, as presented in Figure 2. In some circumstances these 
complexes can activate the immune system and induce the generation of antibod-
ies. The immune response can be innate, mediated via the toll-like receptors, and 
adaptive with a T cell-mediated response, followed by the generation of antibodies. 
The three isotypes (IgG, IgA, or IgM) can be present [13, 19], but IgGs are formed 
very rapidly, which is unusual in the early stage of the immune response, and IgGs 
can become rapidly pathogenic [19]. In rare cases, only IgA (especially in patients 
with cancer) or IgM isotypes are identified [39]. Following heparin treatment 
cessation, antibodies disappear from blood circulation within about 3 months. The 
respective concentrations of PF4 and heparin in blood circulation or at pathological 
sites are key factors for inducing immunogenicity [40, 41]. The clinical context is 
then a risk factor for heparin-dependent antibodies’ development. Another initial 
cause which can favor generation of antibodies has been described and concerns 
a previous exposure of patients to bacterial infections [42]. PF4 can complex with 
bacterial polysaccharides and then becomes immunogenic. The immune response 
induces generation of antibodies to this chemokine. When patients with this 
former stimulation receive heparin, PF4 released from endothelium forms HPF4 
complexes which reactivate the immune system (Figure 1), and IgG isotypes are 
rapidly generated. In addition to PF4, heparin treatment (and more especially 
LMWH) can also release tissue factor pathway inhibitor (TFPI) bound to ECs into 
blood circulation. No immune reaction to TFPI has been observed until now, but its 
increased concentration contributes to elevate the anticoagulant activity of heparin 
at the beginning of treatment.
4. Heparin-dependent antigens in HIT
The major heparin-dependent antigen involved in HIT/HITT is PF4, a CXC chemo-
kine present in platelet α-granules and released upon platelet activation and aggrega-
tion. PF4 is a 70 amino acid (AA) protein with a MW of 7800 kDa, released in blood 
circulation as a tetramer with a MW of about 30 kDa [34–36, 43]. This chemokine has a 
structure involving one α-helix and three β-sheets organized in an antiparallel manner; 
it is highly electropositive, with many lysine and arginine residues, and has two disulfide 
bridges per monomer. The tetramer is organized in such a way that it exposes an exter-
nal ring of positive charges, as shown in Figure 3. The formation of HPF4 complexes 
depends on the respective concentrations of heparin and PF4 [13, 24, 44]. Stoichiometric 
complexes are formed at a concentration of about 150 μg of heparin (i.e., about 27 IU 
UFH) per mg of PF4 (Figure 4). High- and low-affinity heparin molecules have the 
same reactivity with PF4, as well as LMWH, and the sulfation grade is of essence for 
these interactions. Patients who develop antibodies are those with the highest extracellu-
lar concentrations of PF4 in blood circulation, or at pathological sites, and with heparin 
concentrations permitting the formation of stoichiometric HPF4 complexes.
If heparin treatment is given through continuous infusion, heparin concentra-
tion remains constant in blood circulation, and the risk to form stoichiometric 
HPF4 reactive complexes is reduced. When heparin is given through the subcutane-
ous route, blood concentrations present high variations, from <0.1 IU/ml at trough 
to >0.7 IU/ml at peak. For current curative UFH treatments (2–3 injections/day), 
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the PF4 concentrations needed for forming stoichiometric complexes must be of 
about 4 μg/ml for heparin concentrations ≤0.1 IU/ml (trough) or of ≥28 μg/ml for 
heparin concentrations ≥0.7 IU/ml (peak). Required PF4 concentrations are high 
comparatively to expected heparin concentrations in blood circulation, even in 
Figure 4. 
PF4 is released from platelets as a complex with a proteoglycan dimer and is displaced by heparin for which 
it has a higher affinity. Complexes of heparin and PF4 depend on their respective ratios. When heparin and 
PF4 are at a stoichiometric concentration, large multimolecular complexes are formed and can be exposed on 
platelets or other blood cells. They can bind heparin-dependent antibodies and focus the deleterious immune 
reaction onto these cells. This can induce HIT or HITT in some patients.
Figure 3. 
Reaction of heparin with PF4 tetramers at stoichiometric concentrations. There is an intimate interaction 
between the ring of positive charges on the PF4 tetramer and the negative charges of the sulfated polysaccharide, 
heparin. This strong interaction induces an alteration of PF4 structure, rendering it immunogenic. Heparin 
(UFH or LMWH) molecules with at least 12 monosaccharides are required for this interaction.
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disease states, but these high concentrations could be present at pathological sites. 
In ECC, blood heparin concentrations are high (about 4–5 IU/ml) and constant: for-
mation of stoichiometric complexes can only occur with 25–30 μg/ml of PF4, which 
is unlikely. For information, the total amount of PF4 releasable from platelets, when 
they are totally activated and aggregated, is of about 5 μg per ml of blood (depend-
ing on platelet count and PF4 content; it is of ±12.5 ng/106 platelets).
But PF4 can accumulate and be at higher concentrations at pathological sites. 
Immunogenic stimulation occurs when body detects a non-self-component, which can 
be heparin used as anticoagulant. When bound to PF4, it forms large complexes, which 
can activate the immune response, which is targeted to these complexes and possibly 
extended to PF4 itself, through epitope spreading. Generated antibodies can be consid-
ered as alloantibodies. In few cases, PF4 antibodies can be pre-existing chronically or 
generated transitory as a side response to an infectious disease [14, 42, 45].  
Anti-PF4 autoantibodies can bind to HPF4 complexes formed during heparin therapy 
and are then targeted to platelets or other blood cells which expose HPF4 complexes, 
focusing the deleterious immune response [22, 29, 30, 46]. In few cases, non-PF4 
antigens can be involved [14, 15, 17, 46, 47]. HIT/HITT presentation and disease 
kinetics are then frequently atypical, although a moderate or characteristic thrombo-
cytopenia develops during heparin therapy. IL8 has been reported in some patients as 
another heparin-dependent antigen in HIT/HITT. Anti-IL8 antibodies are pre-existing 
in many patients with chronic inflammation and are generated as a regulatory response 
to control this pathological context. Pathogenicity can occur because IL8 can bind 
heparin, and these complexes are fixed onto platelets and other blood cells through IL8 
receptors (IL8-RA and IL8-RB) or through direct heparin binding [37, 38].  
Interestingly, heparin binding to platelets increases with their activation grade. 
Anti-IL8 antibodies then focus the immune response deleterious effects to blood cells 
exposing heparin IL8 complexes which are then activated or destroyed. Neutrophil-
activating peptide 2 (NAP-2), the β-thromboglobulin precursor, is another platelet 
CXC chemokine reported as a possible heparin-dependent antigen in rare HIT cases 
[14]. Lastly, in patients undergoing ECC [16, 26, 27], heparin is used as anticoagulant 
and is neutralized with a defined concentration of PrS at the end of the process. Anti-
PrS or anti-heparin-PrS antibodies have been the only ones identified in few patients 
treated with heparin and presenting with a HIT-/HITT-like syndrome [17], with a pos-
sible fatal outcome. These antibodies can activate platelets in the presence of heparin 
[15, 46, 47]. Recent investigations have shown that anti-PrS antibodies are rather 
frequent in patients receiving this drug for heparin neutralization, but only very few of 
them develop severe clinical complications. Recurrent ECC in the same patient, with 
various exposures to heparin and PrS over time, can be an increased risk for develop-
ment of antibodies and associated pathogenicity, with a HIT-/HITT-like syndrome.
5. Pathogenicity and mode of action of heparin-dependent antibodies
Heparin-dependent antibodies, and especially those to HPF4 complexes, induce 
thrombocytopenia and thrombosis in some clinical circumstances [46]. Particularly 
IgG isotypes can activate platelets, ECs, or other white blood cells such as monocytes, 
when they bind to their target antigenic structure, present at the surface of these 
cells [28, 29, 44, 46, 47]. There is now evidence that heparin and HPF4 complexes 
bind to platelets’ surface, and this binding increases with their activation grade. 
HPF4 complexes fix antibodies and target the immune response, provoking platelet 
activation, aggregation, and interaction with other blood cells. During the process, 
IgGs react with platelet CD32, which is the FcɣRIIa receptor [44, 46]. This contrib-
utes to amplify platelet activation and aggregation. The CD32 surface density is an 
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important factor for the amplitude of platelet activation induced by antibodies. In 
patients with platelets presenting a CD32 polymorphism (131 Arg-His), activation is 
enhanced: the 131-Arg-His heterozygous or 131-His-His homozygous CD32 pheno-
types are more reactive than the 131-Arg-Arg one. The patient propensity to develop 
HIT or HITT can depend on platelet activation grade and density or polymorphism 
of CD32. Antibodies to HPF4 can activate ECs and monocytes, favoring the release 
of TF, a potent procoagulant starter [29, 30]. In patients with HIT/HITT, neutrophils 
are activated and form aggregates with platelets, which can be detected in blood 
circulation. Therefore, the presence of anti-HPF4 IgG antibodies initiates multiple 
abnormal activities in blood circulation, which induce platelet activation and 
destruction and a concomitant prothrombotic risk (Figure 5). Blood activation can 
be out of control from body’s antithrombotic defenses, which are overwhelmed, and 
thrombosis occurs. Interestingly, thrombosis tends to occur at pre-existing patho-
logical sites, where blood activation and inflammation are already activated, and 
the risk is greatly amplified by anti-HPF4 antibodies, as summarized in Figure 4. 
We have the experience that an additional factor is very important for the initiation 
and amplification of the pathological process. This concerns the antibody avidity 
for HPF4 complexes [20]. In three patients with HIT or HITT, we succeeded to 
separate anti-HPF4 IgGs into two groups: the most important (>90%) one had a low 
affinity for HPF4 and no or only a weak platelet activation capacity, while the minor 
one (≤10%) activated highly platelets, as evidenced with the C14-serotonin release 
assay. In few cases, only IgA isotypes specific for HPF4 complexes were identified in 
patients with HITT and malignant diseases. Although rare, IgAs can be pathogenic in 
some autoimmune disorders [49, 50], and this is not unexpected to note their effect 
in HIT. More rarely, IgM can be present at high concentration in patients with HIT, 
without IgGs. The mechanisms involved are not totally understood, but recently 
it was demonstrated that anti-HPF4 IgM antibodies can activate complement and 
induce platelet destruction [39]. Altogether, the different activities described here 
above help to understand why HPF4 antibodies, including IgG isotypes, can remain 
Figure 5. 
Scheme showing how heparin-dependent antibodies, targeted to HPF4 complexes, bind to platelets and 
endothelial cells but also to monocytes and induce platelet and EC activation, monocyte stimulation, release of 
TF, and formation of aggregates, all contributing to thrombocytopenia and thrombosis.
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asymptomatic in many patients and produce (especially IgG isotypes with high HPF4 
affinity) HIT or HITT only in a few of them. The pathogenic process is multifactorial 
and involves activation and interaction of various blood cells, with the prothrom-
botic activity of TF. Patients’ pathophysiological history and clinical status provide 
additional risk factors for the occurrence of disease [5, 6].
Nevertheless, there is still a fortuity context for the occurrence of the HIT/HITT 
complication, which relies on the formation of the immunoreactive HPF4 com-
plexes, requiring defined concentrations of PF4 and heparin, exposed on blood cells 
[48]. This is a pre-requisite condition for permitting the binding of antibodies and 
starting the pathogenic process. This explains why this disease develops so rapidly 
when the critical conditions are met.
6. Diagnosis of heparin-induced thrombocytopenia
Many different assays are available for the diagnosis of heparin-dependent 
antibodies and for testing their capability to activate platelets. They are classified 
into two groups: immunoassays [23, 25, 51, 52], developed following the discovery 
of PF4 as the major target heparin-dependent antigen, and functional assays, 
performed with a low and a high heparin concentration, which were already used 
before [53]. A murine monoclonal antibody (KKO) has been developed and mim-
ics HIT-associated antibodies, with platelet activation capability [54]. Here below 
we discuss the laboratory methods, and their combination, for the diagnosis of 
HIT/HITT. Diagnosis combines the clinical probability pretest with laboratory 
investigations [25]. For laboratory testing, the specimen used is plasma or serum for 
immunoassays and citrated plasma or heat-inactivated serum for functional assays. 
These techniques provide a laboratory support to establish, confirm, or exclude 
the diagnosis of HIT/HITT and must always be used in association with the pretest 
clinical probability. When HIT is suspected with a characteristic thrombocytopenia, 
heparin must be discontinued and replaced with another anticoagulant.
6.1 Immunoassays for heparin-dependent antibodies
With the discovery of the major target antigen for heparin-dependent antibodies, 
i.e., HPF4 complexes, immunoassays were developed, optimized, and standard-
ized [23, 24, 52]. The first immunoassay introduced was a two-site enzyme-linked 
immunosorbent assay (ELISA), for measuring antibodies to HPF4 [12]. The antigen, 
HPF4, is coated on the plate, which is then saturated and stabilized. A well-defined 
stoichiometric concentration of PF4 tetramer and heparin (about 150 μg heparin per 
mg PF4) must be used for presenting epitopes reactive with antibodies. Heparin-
dependent antibodies can be caught from the diluted tested plasma or serum (usually 
a 1:100 dilution is used), during the first incubation step. Following a washing step, 
the immunoconjugate, specific for human immunoglobulins or their isotypes, is 
introduced, and a second incubation step is performed. The immunoconjugate is 
often a rabbit or goat antibody, specific for human whole immunoglobulins (IgGAM) 
or for only an isotype (IgG, IgA, or IgM), and labeled with peroxidase. In current 
practice, this tag reagent is an antihuman IgG-peroxidase conjugate. Following a new 
washing step, the substrate is introduced, and a color develops. Tetramethylbenzidine 
(TMB) with hydrogen peroxide (H2O2) is now the most often used substrate, produc-
ing a blue color, which turns yellow when the reaction is stopped with sulfuric acid. 
Absorbance is measured using a microplate reader at 450 nm. Different variant meth-
ods have been introduced. Heparin can be replaced with another sulfated polymer 
(electronegative) such as polyvinyl sulfonate. However, using heparin matches better 
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with the context of antibody generation and in vivo pathogenicity. Magnetic latex 
particles can be used in place of the solid phase capture micro-ELISA. Different tag 
antibody labels can be used instead of peroxidase, such as alkaline phosphatase (with 
its appropriate substrate). The “enzyme-substrate” detection system with chemilu-
minescence or fluorescence can also be used (direct measurement). Combining latex 
magnetic particles and chemiluminescence or fluorescence allows immunoassay 
automation. Lastly, performing immunoassays in the presence of an excess of heparin 
allows confirming antibody specificity [25, 55].
Figure 6 shows the general immunoassay principle for detecting heparin-depen-
dent antibodies. For testing the non-PF4 antigen-dependent antibodies, similar 
immunoassays can be designed by replacing PF4 with the concerned protein (e.g., 
IL8 or PrS). We developed an original patented approach, where heparin in excess is 
coated in the presence of PrS and remains biologically available. The tested patient’s 
sample is then incubated in the presence of a concentrated platelet lysate (containing 
all the platelet releasable proteins, but not plasma factors). If antibodies are present, 
a ternary complex is formed between tetrameric PF4 (or eventually another platelet 
protein), immobilized heparin, and antibodies. Caught antibodies are then detected 
as previously described [24]. This method offers a kinetic model for testing antibod-
ies and mimics their binding to heparin-protein complexes bound onto platelet or 
blood cell surfaces. This assay reflects better the mechanisms occurring in pathology 
and offers improved and optimized sensitivity and specificity.
6.2 Platelet activation methods for disease confirmation
Functional assays rely on testing the capability of heparin-dependent anti-
bodies to activate platelets at a low (0.1–1.0 IU/ml) and a high (10–100 IU/ml) 
heparin concentration. In HIT/HITT, platelets are only activated at the low heparin 
Figure 6. 
General principle of immunoassays used for heparin-dependent antibodies, either globally or for specific 
isotypes. Enzyme tag with substrate is used in ELISA. Chemiluminescent immunoassays, using magnetic latex 
particles, can be automated on immunological analyzers. Using heparin in excess in sample diluent allows 
confirming antibody specificity.
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concentration. Functional assays need to use normal donor platelets, freshly 
prepared. They must be duly selected for the right reactivity. This is the constraint 
which limits the use of this technique. Platelets are used as platelet-rich plasma 
(PRP) or as washed platelets. What induces donor to donor responsiveness in 
platelet activation assays used for HIT antibodies is not totally understood. The 
CD32 platelet density or His polymorphism could favor reactivity. In practice, 
platelets need to be qualified with a known positive sample for their appropriate-
ness. Frequently, platelets from four normal donors are used, and the assay is 
positive if at least two out of the four donors give a positive platelet activation test. 
Other factors can regulate platelet activity, and interestingly washed platelets are 
usually more reactive than PRP. This can be explained by some platelet activation 
induced by the washing process, and a higher amount of PF4 is present on platelet 
surface. Functional assays concern PAT, SRA, heparin-induced platelet activation 
(HIPA), and flow cytometric assays (FCA); but other assays have been reported 
and elegantly reviewed in 2017 [53]. PAT is a simple aggregation assay performed 
with PRP and the tested patient citrated plasma. SRA is performed with washed 
platelets labeled with C14, incubated with tested patient’s plasma, and released 
C14-serotonin is measured. HIPA is also performed with washed platelets, incubated 
with the tested sample, and platelet activation/aggregation is visually evaluated. 
FCA is a technique that requires to mix PRP (washed platelets are possible) with 
patient’s citrated plasma and to measure platelet activation through the expression 
Figure 7. 
Scheme showing the algorithm for the diagnosis of HIT/HITT: when suspected (thrombocytopenia and/or 
thrombosis), the disease diagnosis involves the clinical probability estimation and laboratory testing, first with 
immunoassay, which allows ruling out disease when not present, and then with a confirmatory functional assay.
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of P-selectin [24]. FCA can also be used for the measurement of antibody-induced 
release of platelet microparticles. SRA is considered as the reference and most sensi-
tive method. PAT has a poor sensitivity. HIPA needs trained laboratory operators 
and is mainly used in Germany and some neighboring countries. FCA is now a more 
standardized approach and looks promising but needs to be confirmed through 
practical experience in clinical laboratories. This method can be available in many 
centers for testing in emergency, provided a flow cytometer and fresh platelets are 
available.
6.3 Diagnostic approach for HIT/HITT
The diagnosis of HIT/HITT must be done accurately and reliably for a safe 
management of concerned patients [25]. The first alert signal is thrombocytopenia 
occurring 5–15 days following the onset of heparin therapy or earlier if the patient 
had a previous exposure to that drug within the 3 preceding months. HIT, or HITT 
if thrombosis is present, is then suspected and must rapidly be confirmed. If this 
complication is excluded, patients can continue to receive heparin, the most effec-
tive anticoagulant in many critical clinical situations. If the disease is confirmed or 
cannot be excluded, or if HIT is suspected but the diagnosis cannot be conducted, 
heparin must be replaced by another anticoagulant, according to the clinical context 
and practitioners’ experience. Figure 7 shows an algorithm for establishing or 
excluding the diagnosis of HIT. When HIT is suspected, the pretest clinical prob-
ability must be evaluated with the 4Ts method or another one in use in the clinical 
setting [28]. The 4Ts score is simple and relatively well-standardized. When HIT/
HITT is suspected, heparin is immediately stopped, and another anticoagulant is 
used to avoid any risk of severe complication. Nevertheless, the diagnosis must be 
established and confirmed, as the patient can need heparin later. The first labora-
tory investigation involves immunological testing for antibodies. If the test is nega-
tive, and the clinical probability is low or moderate, HIT can be excluded. But if 
clinical probability is high, HIT cannot be excluded and remains possible with non-
PF4 heparin-dependent antigens involved. If positive, antibodies are present. HIT 
develops mainly when IgGs are generated and present at high concentration. Many 
authors consider that HIT occurs when the optical density (OD) in ELISA is >1.00 
(the cutoff value for the positive range being at ≥0.5). When the IgG immunoassay 
is positive, a functional assay must be performed for confirming the diagnosis, as 
many heparin-dependent antibodies are asymptomatic. This functional assay must 
be as sensitive and specific as possible. In any case if clinical probability is high, the 
possibility of HIT complication remains present, whether the laboratory testing is. 
Testing must be repeated [56], and other antigens than HPF4 can be investigated.
7.  Cross-reactivity of the various heparins, heparin-like compounds, or 
danaparoid sodium
HIT/HITT is associated with UFH or LMWH therapy, both drugs being sulfated 
polysaccharides. Other heparin-like anti-FXa anticoagulants, such as fondaparinux 
or danaparoid sodium, do not generate drug-specific antibodies [7, 10]. However, 
cross-reactivity of these drugs with antibodies present in patients with character-
ized HIT/HITT can be observed in laboratory assays [57]. This cross-reactivity has 
been reported for danaparoid sodium when it is tested in the immunoassay at a 
high concentration in the presence of PF4 (about 3.00 mg danaparoid sodium per 
mg of PF4). This can be due to the high-affinity heparan sulfate component pres-
ent in this drug, which represents about 4% of the total. Cross-reactivity has also 
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been reported in functional assays. However, there is no evidence that danaparoid 
sodium can generate drug-induced antibodies, and cross-reactivity is opposed 
by the other non-affinity components (about 80% low-affinity heparan sulfate, 
12% dermatan sulfate, and 4% chondroitin sulfate), present in large excess, which 
disrupt the possible complexes formed, as do other low-sulfated polysaccharides 
[9, 58]. Therefore, there is no evidence that danaparoid sodium can provoke HIT/
HITT, and the reported results and long-term clinical experience in many countries 
suggest that cross-reactivity is totally inhibited by the major non-affinity fractions. 
Furthermore, danaparoid sodium at therapeutic concentrations can inhibit the 
heparin-induced platelet aggregation. Conversely, pentosan polysulfate was found 
to be as effective as heparin and to form complexes with PF4 at similar ratios than 
UFH, for binding all heparin-dependent antibodies [8, 14]. Lastly, fondaparinux is 
not expected to induce drug-dependent antibodies or to cross-react with existing 
antibodies [32].
8. Conclusions and perspectives
In this chapter we have reviewed the present understanding of the generation of 
heparin-dependent antibodies in UFH- or LMWH-treated patients, which are the 
primary cause for HIT/HITT and a major adverse effect of heparin therapy. This risk 
is much higher when UFH is used, and disease develops more frequently in some clin-
ical situations including cardiac or orthopedic surgery, traumatology, or malignancy. 
The occurrence of HIT/HITT tends to decrease thanks to a better control of therapy 
with UFH, shorter treatment times, and the use of LMWH when possible. When 
heparin therapy needs to be stopped, a large panel of alternative anticoagulants is 
available, although in some applications heparin remains the most effective one.
The mechanisms, which can induce generation of heparin-dependent antibod-
ies, and pathogenicity for some of them have been extensively described and 
discussed in literature [14, 19, 20, 22, 42, 46]. Immunization develops when defined 
concentrations of heparin and PF4, forming stoichiometric multimolecular com-
plexes, are present. In vivo, immunogenic complexes with PF4 can also be formed 
with other polyanions such as polyphosphates [59]. Various isotypes can be gener-
ated, IgM, IgA, or IgG, but almost all clinical complications of this iatrogenic dis-
ease are reported with IgGs present at high concentration and with high affinity. For 
HIT/HITT pathological development, various patient-associated and fortuity fac-
tors are required. Stoichiometric HPF4 complexes must be present for stimulating 
the immune system and developing antibodies but also for expressing pathogenic-
ity. Heparin-dependent antibodies are harmful only if they bind to target antigenic 
structures (mainly HPF4 stoichiometric complexes), present on platelets, ECs, or 
other blood cells, focusing the immunological response. The immune system is then 
deviated from its protective role and destroys the patient’s own cells [60].
HIT/HITT diagnosis is of essence for confirming or excluding this disease, and 
heparin treatment can be continued if the risk is ruled out. The first step when throm-
bocytopenia and/or thrombosis occur is to suspect this heparin adverse effect and to 
evaluate the pretest clinical probability. The 4Ts score is frequently used and allows 
risk classification from 0 to 8, 6–8 being the highest risk. Concomitantly, performing 
an immunoassay allows to detect and to measure IgG heparin-dependent antibodies 
targeted to HPF4. If the assay is negative and if clinical probability is low or moder-
ate (score ≤ 5), HIT can be excluded, but patients need to be monitored closely, 
especially if thrombocytopenia is not corrected. If positive, IgG heparin-dependent 
antibodies are present, and HIT probability is higher if ELISA OD ≥ 1.00. Finally, the 
use of functional assays allows differentiating asymptomatic antibodies from those 
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which can activate platelets and provoke disease. The presence of HIT or HITT is 
confirmed when the functional assay is positive [60]. However, even when negative, 
if clinical probability is high (6–8), HIT/HITT remains possible, and patients must be 
managed accordingly. Heparin cannot be continued in any patient with a possible or 
probable HIT diagnosis, and an alternative anticoagulant must be used.
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